ATOS
Price
$0.82
Change
-$0.02 (-2.38%)
Updated
Jul 28, 04:59 PM (EDT)
Capitalization
105.54M
20 days until earnings call
ZIVO
Price
$11.05
Change
-$0.16 (-1.43%)
Updated
Jul 25 closing price
Capitalization
40.8M
Interact to see
Advertisement

ATOS vs ZIVO

Header iconATOS vs ZIVO Comparison
Open Charts ATOS vs ZIVOBanner chart's image
Atossa Therapeutics
Price$0.82
Change-$0.02 (-2.38%)
Volume$6.79K
Capitalization105.54M
Zivo Bioscience
Price$11.05
Change-$0.16 (-1.43%)
Volume$187
Capitalization40.8M
ATOS vs ZIVO Comparison Chart in %
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZIVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. ZIVO commentary
Jul 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and ZIVO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 29, 2025
Stock price -- (ATOS: $0.82 vs. ZIVO: $11.05)
Brand notoriety: ATOS and ZIVO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 76% vs. ZIVO: 20%
Market capitalization -- ATOS: $105.54M vs. ZIVO: $42.14M
ATOS [@Biotechnology] is valued at $105.54M. ZIVO’s [@Biotechnology] market capitalization is $42.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileZIVO’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • ZIVO’s FA Score: 0 green, 5 red.
According to our system of comparison, ATOS is a better buy in the long-term than ZIVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 4 TA indicator(s) are bullish while ZIVO’s TA Score has 4 bullish TA indicator(s).

  • ATOS’s TA Score: 4 bullish, 5 bearish.
  • ZIVO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ZIVO is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а -3.72% price change this week, while ZIVO (@Biotechnology) price change was -16.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.74%. For the same industry, the average monthly price growth was +20.88%, and the average quarterly price growth was +48.02%.

Reported Earning Dates

ATOS is expected to report earnings on Nov 17, 2025.

ZIVO is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+6.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($106M) has a higher market cap than ZIVO($40.8M). ATOS YTD gains are higher at: -13.452 vs. ZIVO (-50.233). ZIVO has higher annual earnings (EBITDA): -16.29M vs. ATOS (-28.04M). ATOS has more cash in the bank: 65.1M vs. ZIVO (517K). ATOS has less debt than ZIVO: ATOS (0) vs ZIVO (975K). ZIVO has higher revenues than ATOS: ZIVO (122K) vs ATOS (0).
ATOSZIVOATOS / ZIVO
Capitalization106M40.8M260%
EBITDA-28.04M-16.29M172%
Gain YTD-13.452-50.23327%
P/E RatioN/AN/A-
Revenue0122K-
Total Cash65.1M517K12,592%
Total Debt0975K-
FUNDAMENTALS RATINGS
ATOS vs ZIVO: Fundamental Ratings
ATOS
ZIVO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6265
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (24) in the Medical Specialties industry is somewhat better than the same rating for ZIVO (81) in the null industry. This means that ATOS’s stock grew somewhat faster than ZIVO’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ZIVO (100) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

ATOS's SMR Rating (96) in the Medical Specialties industry is in the same range as ZIVO (100) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

ATOS's Price Growth Rating (62) in the Medical Specialties industry is in the same range as ZIVO (65) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

ATOS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as ZIVO (100) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSZIVO
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
86%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 21 days ago
74%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
87%
Aroon
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZIVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DYSL1.85N/A
N/A
Dynasil Corp. of America
THYKF10.76N/A
N/A
THYSSENKRUPP NUCERA AG & CO.
WSRIF0.17N/A
N/A
WESTERN STAR RES INC.
MDTWF2.15N/A
N/A
Mediterranean Towers LTD
FUJHF19.27-0.23
-1.18%
Subaru Corporation

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with PDSB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then PDSB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-2.71%
PDSB - ATOS
45%
Loosely correlated
N/A
ABOS - ATOS
43%
Loosely correlated
-7.01%
BEAM - ATOS
43%
Loosely correlated
-4.10%
NRIX - ATOS
43%
Loosely correlated
+3.56%
RXRX - ATOS
43%
Loosely correlated
-2.77%
More

ZIVO and

Correlation & Price change

A.I.dvisor tells us that ZIVO and APLM have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZIVO and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZIVO
1D Price
Change %
ZIVO100%
-3.17%
APLM - ZIVO
28%
Poorly correlated
+2.25%
LGVN - ZIVO
24%
Poorly correlated
-1.80%
MDXXF - ZIVO
24%
Poorly correlated
-0.28%
AKRO - ZIVO
23%
Poorly correlated
-2.61%
ATOS - ZIVO
23%
Poorly correlated
-2.71%
More